San Diego, CA
May 20, 2010, AndroScience Corporation (ASC) announced today the forming of a
strategic partnership with Orient Europharma Co. Ltd. (OEP) of Taiwan. The
collaborative agreement centers on the clinical development and
commercialization of ASC’s lead therapeutic candidate, ASC- J9® as a
topical anti-acne product. Under
terms of the agreement OEP is responsible for clinical study
expenses related to an ASC-J9® phase IIb multi center trial in
acne vulgaris. Scheduled to commence in September 2010, the 180 patients,
double-blinded, placebo controlled efficacy study will be jointly conducted at
clinical sites in Taiwan and
the USA.
San Diego, CA. - March 6, 2009, AndroScience Corporation (ASCTM), a developmental stage pharmaceutical company announced results of a Phase 2a dose-ranging study of their lead clinical compound for the treatment of acne. The randomized, double-blinded, vehicle-controlled study completed in late 2008 enrolled 186 patients with acne and consisted of twice daily topical applications of ASC-J9®cream for 12 weeks to evaluate safety and ascertain preliminary efficacy.
AndroScience Corporation (ASC), a San Diego-based biotech company, is developing ASC-J9®as a topical agent for the treatment of acne.
AndroScience has completed a $6.4 million private-equity financing. The
company’s latest round of financing was led by President Life Sciences
Co., Ltd., joined by Eminent Venture Capital and other private
investors.
AndroScience Corporation (ASC), a San Diego based biotech company,
is developing ASC-J9 as a topical agent for the treatment of acne.
March 2007 – A potential treatment using AndroScience’s compound, ASC-J9®, for a neurodegenerative disorder is published in Nature Medicine
February 2007 - AndroScience Corporation begins Clinical Trials in Humans with Acne Vulgaris